ArticleFrontiers in immunology2025

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.

Weihao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.